Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 14.3% from a year ago
Common stock stood at $8K at the end of Q1 FY2026, up 14.3% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +14.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 8K USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +12.5%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8K | +14.3% |
| FY2024 | 2024-12-31 | 7K | +0.0% |
| FY2023 | 2023-12-31 | 7K | +40.0% |
| FY2022 | 2022-12-31 | 5K | +0.0% |
| FY2021 | 2021-12-31 | 5K | — |
Common Stock vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +14.3% is the 8th highest of 10, against a peer median of +31.3%.
- Common stock amounts to 0.0% of total assets for BDTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $191.23M USD | +31.0% | +10.0% | 266.3% | |
| Mar 2026 | $64.69M USD | +179666.6% | +34.8% | 0.0% | |
| Dec 2025 | €1.93M EUR | +101.8% | +66.2% | 0.8% | |
| Mar 2026 | $568K USD | +15.9% | +45.9% | 0.3% | |
| Mar 2026 | $291K USD | +36.0% | +1.0% | 0.1% | |
| Mar 2026 | $25K USD | +127.3% | — | 0.0% | |
| Mar 2026 | $21K USD | +31.3% | +44.2% | 0.0% | |
| Mar 2026 | $10K USD | +11.1% | +14.5% | 0.0% | |
| Mar 2026 | $8K USD | +14.3% | +17.0% | 0.0% | |
| Mar 2026 | $6K USD | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BDTX) | — | +31.3% | +24.6% | 0.0% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.8M | 34.32M | 56.22M | 36.44M | 20.99M |
| Short-term Investments | 143.99M | 88.49M | 75.18M | 62.14M | 107.66M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.9M | 2.63M | 2.6M | 3.79M |
| Total Current Assets | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M |
| Property, Plant & Equipment (Net) | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 829K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.24M | 1.17M | 823K | 1.07M | 73K |
| Total Non-current Assets | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M |
| Total Assets | 247.68M | 156.26M | 158.57M | 122.64M | 143.01M |
| Account Payables | 4.11M | 1.88M | 2.32M | 4.01M | 579K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 28.14M | 25.3M | 22.19M | 18.78M | 15.07M |
| Total Liabilities | 51.78M | 40.56M | 41.83M | 39.36M | 30.8M |
| Common Stock | 5K | 5K | 7K | 7K | 8K |
| Retained Earnings | (243.82M) | (334.99M) | (417.43M) | (487.11M) | (464.74M) |
| Accumulated OCI | (414K) | (1.82M) | (27K) | 24K | 101K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 195.9M | 115.7M | 116.74M | 83.29M | 112.21M |
| Total Debt | 28.46M | 28.14M | 25.3M | 22.19M | 18.78M |
| Net Debt | (37.34M) | (6.18M) | (30.92M) | (14.25M) | (2.21M) |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.